Linked Life Data

16460555

Source:http://linkedlifedata.com/resource/pubmed/id/16460555

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2006-2-7
pubmed:abstractText
Vancomycin serum concentrations were determined for 1,737 patients treated with either 2 x 1 g of vancomycin or 4 x 500 mg daily (780 patients), according to current nomograms, or by continuous infusion (957 patients) with a loading dose (1 g) and a total of 2-6 g daily. Trough serum concentrations were determined after 36-48 h. Adequate serum levels for the treatment of a normal methicillin-resistant Staphylococcus aureus (MRSA) and a glycopeptide-intermediate S. aureus (GISA) were observed in 81% and 20.9% of patients, respectively. The data support theoretical arguments that higher and more sustained serum levels of vancomycin, obtained by continuous infusion, may enhance clinical efficacy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1198-743X
pubmed:author
pubmed:issnType
Print
pubmed:volume
12
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
92-5
pubmed:dateRevised
2006-11-7
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
Monitoring of vancomycin serum levels for the treatment of staphylococcal infections.
pubmed:affiliation
Clinical Microbiology Laboratory, Hospital Saint Joseph, 75014 Paris, France.
pubmed:publicationType
Journal Article